The combination of a tyrosine kinase inhibitor with an immune checkpoint inhibitor significantly improved progression-free survival in patients with hepatocellular carcinoma, shows a new study.
Individual patient data is available for less than half of the clinical trials that underpin the FDA approval of new cancer drugs, a new analysis reveals.
Mark Cuban has launched a discount pharmacy offering generic drugs at a substantially lower cost than current retail pricing, and currently has several cancer drugs in the formulary.